Literature DB >> 11298603

Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages--studies in a rat model.

J L Teeling1, W K Bleeker, G M Rigter, N van Rooijen, T W Kuijpers, C E Hack.   

Abstract

Despite widespread use in various immune disorders, the in vivo mechanisms of action of intravenous immunoglobulin (IVIG) preparations are not well known. We previously reported that human neutrophils degranulate after incubation with IVIG in vitro as a result of interaction with FcgammaRII. The purpose of this study was to determine whether IVIG might stimulate neutrophils in vivo. Anaesthetized rats received a bolus intravenous injection of IVIG preparations, containing either high (aged IVIG) or low (fresh IVIG) amounts or IgG dimers at a dose of 250 mg/kg. Administration of aged IVIG induced neutrophil activation in vivo, whereas no effect was observed after infusion of fresh IVIG. Histological examination of lung tissue demonstrated mild influx of neutrophils into the pulmonary tissue after aged IVIG administration, though gross damage did not occur. Macrophage-depleted rats no longer showed activation of neutrophils after infusion of aged IVIG, suggesting that neutrophils become activated via an indirect macrophage dependent way. We conclude that IVIG induces a mild activation of neutrophils in vivo via triggering of macrophages depending on the amount of IgG dimers. For this reason, IVIG preparations with a high content of dimers may not always be as harmless as generally believed and may be responsible for some of the side-effects observed during IVIG infusions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298603     DOI: 10.1046/j.1365-2141.2001.02674.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

3.  Immunoglobulin Therapy in a Patient With Severe Chikungunya Fever and Vesiculobullous Lesions.

Authors:  Ana Isabel V Fernandes; Joelma R Souza; Adriano R Silva; Sara B S C Cruz; Lúcio R C Castellano
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

4.  Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation.

Authors:  Iwan Kustiawan; Ninotska I L Derksen; Theresa Guhr; Simone Kruithof; Wim Jiskoot; Gestur Vidarsson; Theo Rispens
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.